In 658 patients with MASH followed for a mean of 14 months after starting resmetirom (Rezdiffra) in routine GI care, liver enzymes, liver stiffness, liver fat, and FAST scores all declined, and about half of patients with FibroScan results moved to a lower liver stiffness category.
Madrigal Pharmaceuticals is presenting these findings as Poster 3516 at The Liver Meeting (AASLD) in Denver, November 5 to 9, 2026, with Latica as research partner. The study used the Latica real-world data repository, which compiles de-identified EMR data from Gastro Health, with authors from Madrigal, Broadstreet HEOR, Latica, Gastro Health, and Summit Clinical Research.
Why real-world data matters here
Resmetirom, an oral thyroid hormone receptor β-selective agonist, received accelerated FDA approval in March 2024 for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, after the Phase 3 MAESTRO-NASH trial showed it outperformed placebo on MASH resolution and fibrosis. Clinical trials establish efficacy under controlled conditions. Real-world data answer a different set of questions:
- Who is actually being prescribed the therapy in routine practice?
- How do liver and metabolic markers change outside a trial setting?
- How does treatment interact with other common therapies, such as GLP-1 receptor agonists?
How the study was designed
A single-arm, retrospective cohort study using the Latica real-world gastroenterology data repository, sourced from Gastro Health’s network of more than 400 physicians at 152 locations across 7 states.
Population
Adults with at least one resmetirom prescription between April 2024 and April 2025, and at least one encounter 12 or more months after starting.
Exclusion
compensated or decompensated cirrhosis in the 2 years before starting, identified with a validated diagnostic code algorithm
Index date and baseline
first resmetirom prescription, with baseline assessed over the prior 12 months
Measures
ALT, AST, FIB-4, BMI, weight, FibroScan liver stiffness (VCTE) and CAP, FAST score, cardiometabolic risk factors, concomitant medications, and treatment-related adverse events
Responder thresholds
ALT reduction of 17 U/L or 20%; FAST reduction of 0.22 or more; liver stiffness reduction of 25% or 30%; CAP reduction of more than 40 dB/m
Who is starting resmetirom
Of 2,147 patients who started resmetirom, 772 (36%) had at least 12 months of follow-up. After excluding 114 with prior cirrhosis, 658 were analyzed. Mean follow-up was 14 months.
Demographics
mean age 58.6 years; 56% female; 62% in Florida
Weight
68% with BMI 30 or higher, 25% with BMI 25 to under 30
Cardiometabolic risk
97% had at least one risk factor, 88% two or more, and 65% three or more; hypertension (76%), dyslipidemia (71%), obesity (70%), type 2 diabetes (61%)
Concomitant therapy during follow-up
statins (51%), GLP-1 RAs (36%, one in five of them at high dose), SGLT2 inhibitors (9%), pioglitazone (under 2%)
What changed in 12 months
Among patients with values at both baseline and follow-up, every measure declined, and all changes were statistically significant.
| Measure | Patients (n) | Baseline mean | Follow-up mean | Mean change | Median change |
|---|---|---|---|---|---|
| ALT (U/L) | 410 | 57.6 | 40.3 | −17.3 | −6.5 |
| AST (U/L) | 409 | 44.7 | 34.4 | −10.2 | −4.0 |
| FIB-4 | 290 | 1.7 | 1.6 | −0.1 | −0.1 |
| FibroScan liver stiffness (kPa) | 112 | 10.0 | 8.8 | −1.2 | −2.2 |
| CAP, liver fat (dB/m) | 112 | 321.0 | 285.2 | −35.8 | −30.0 |
| FAST score | 85 | 0.4 | 0.3 | −0.1 | −0.1 |
| BMI (kg/m²) | 525 | 33.9 | 32.9 | −1.0 | −0.6 |
| Body weight (kg) | 526 | 96.2 | 93.4 | −2.7 | −1.8 |
Shifts in liver stiffness (112 patients with FibroScan results):
- 52% moved to a lower liver stiffness category, 36% stayed in the same category, and 12% moved higher
- 70% (32 of 46) who started at 10 to under 20 kPa moved below 10 kPa
- The share of patients above 8.0 kPa fell from 83% to 50%
Responder rates at follow-up:
| Endpoint (n) | Improved | Stable | Worsened |
|---|---|---|---|
| ALT, 17 U/L or 20% reduction (410) | 50% | 27% | 23% |
| Liver stiffness, 25% reduction (112) | 47% | 42% | 11% |
| CAP, more than 40 dB/m reduction (112) | 46% | 40% | 14% |
| Liver stiffness, 30% reduction (112) | 38% | 53% | 9% |
| FAST, 0.22-point reduction (85) | 35% | 55% | 10% |
In addition, 12% of patients reduced their BMI by 10% or more, and 11% reduced their body weight by 10% or more.
Safety: 10.6% of patients (70) had at least one treatment-related adverse event recorded, most often diarrhea (7.3%) and nausea (4.0%). Pruritus and vomiting were each about 2%.
The authors conclude that resmetirom use was associated with clinically meaningful improvements over follow-up, consistent with the 52-week MAESTRO-NASH results, and that larger studies with longer follow-up are needed to confirm them.
How to read these results
This is a descriptive analysis, not a comparative effectiveness study.
- There is no comparator group, so changes cannot be attributed to resmetirom alone
- 36% of patients also used a GLP-1 RA and 51% a statin during follow-up, which may affect liver and weight measures
- Follow-up values were available for subsets of patients (FibroScan for 112, FAST for 85)
- The comparison with MAESTRO-NASH is qualitative; the poster does not show trial data side by side
- Adverse events drawn from records may be undercounted, adherence could not be confirmed, and data come from one health system
How to read these results
The study was possible because the data come from specialty care, where MASH is diagnosed and managed. Records from Gastro Health’s community GI practices include the measures hepatologists use to assess and monitor disease, such as VCTE liver stiffness, CAP, and FAST scores, alongside labs, medications, and comorbidities. Claims-based datasets typically lack these clinical values.
Linking those measures across each patient’s care is what allowed the research team to follow 658 patients for a mean of 14 months. Earlier analyses from the same data source were presented at Liver Connect 2025 and AASLD 2025.
View the Full AASLD The Liver Meeting Poster
Madrigal 2026 AASLD Posters
Poster
3516, “A 12-Month Real-World Assessment of Clinical Characteristics and Biomarker Changes Following Resmetirom Initiation in Patients with MASH: A Descriptive Cohort Study Using Electronic Medical Records in the United States”
Event
The Liver Meeting (AASLD), Denver, November 5 to 9, 2026; abstract published in Hepatology, pages S1807 to S1808
Authors
Yestle Kim, John O’Donnell, Christina Parrinello (Madrigal Pharmaceuticals); Romina Fakhraei, Karissa Johnston, Andrew Kennedy, Emily Mercer (Broadstreet HEOR); Yael Silberberg, Robert Eisdorfer, Karin Keren (Latica); Rajagopal Chadalavada, Pradeep Bekal (Gastro Health); Naim Alkhouri (Summit Clinical Research)
Exploring real-world evidence in GI or hepatology? Contact Latica at [email protected] to request a data feasibility assessment.
